Drug Trial Radar · NCT03618355
Trial of eRapa in Prostate Cancer Patients
Last checked: Nov 19, 2026Latest source record: Mar 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Aug 28, 2018
Primary completion
Dec 2, 2019
Study completion Dec 2, 2019
Sponsor
- Lead sponsor
- Rapamycin Holdings, Inc. dba Emtora BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Cancer Insight, LLC
- First posted
- Aug 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to determine the safety, pharmacokinetics/pharmacodynamics, and immunologic impact of encapsulated rapamycin in patients with low risk prostate cancer under active surveillance. There will be four groups of patients, each receiving a different dose of rapamycin.
Conditions
- Prostate Cancer
Interventions
eRapa (encapsulated rapamycin)Drug
The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100). This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)Time frame: After 4 weeks of treatment in each dosing cohort.
- Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)Time frame: After completion of treatment, approximately 12 weeks, in each dosing cohort.
- Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)Time frame: This will be completed after all dosing cohorts have been enrolled and treated, anticipated to occur at 1 year.
- Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)Time frame: This will be completed after all dosing cohorts have been enrolled and treated, anticipated to occur after 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UT Health San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.